WAS
TARO icon

WESPAC Advisors SoCal’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

WESPAC Advisors SoCal’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$32K – 335
2019
Q1 		$32K Sell
300
-330
-52% -$32.9K 0.02% 137
2018
Q4 		$53K Buy
+630
New +$60.7K 0.03% 118

Other funds holding TARO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Claret Asset Management
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

WESPAC Advisors SoCal's TARO Position: Q2 2019 in Review

WESPAC Advisors SoCal sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2019, closing a stake of 300 shares — an estimated $32K sold.

WESPAC Advisors SoCal first reported a position in TARO in Q4 2018 and held it in 2 quarters. The position peaked at $53K in Q4 2018. 105 funds tracked by Wall St. Rank hold TARO as of Q2 2019.

  • WESPAC Advisors SoCal reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2019 after selling out during the quarter.
  • WESPAC Advisors SoCal sold 300 Taro Pharmaceutical Industries Ltd. shares in Q2 2019, an estimated $32K.
  • WESPAC Advisors SoCal first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2018 and held it in 2 quarters.
  • WESPAC Advisors SoCal's Taro Pharmaceutical Industries Ltd. position peaked at $53K in Q4 2018.
  • 105 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2019.

Based on WESPAC Advisors SoCal's 13F filing for Q2 2019, filed 30 Jul 2019.